Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial

Andrea Necchi(Vita-Salute San Raffaele University), Roberto Salvioni(Neurology, Inc), Cinzia Ortega(Candiolo Cancer Institute), Teodoro Sava(University of Verona), Maria Grazia Daidone(Fondazione IRCCS Istituto Nazionale dei Tumori), Rodolfo Lanocita(Fondazione IRCCS Istituto Nazionale dei Tumori), Marzia Pennati(Fondazione IRCCS Istituto Nazionale dei Tumori), Lawrence H. Schwartz(Memorial Sloan Kettering Cancer Center), Nicola Nicolai(Fondazione IRCCS Istituto Nazionale dei Tumori), Nadia Zaffaroni(Fondazione IRCCS Istituto Nazionale dei Tumori), Carlo Morosi(Fondazione IRCCS Istituto Nazionale dei Tumori), Patrizia Giannatempo(Fondazione IRCCS Istituto Nazionale dei Tumori), Luigi Mariani(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandro M. Gianni(University of Milan), Cosimo Sacco(Ospedale Santa Maria della Misericordia di Udine), Filippo de Braud(University of Milan), Flavio Crippa(National Cancer Institute), Caterina Messina(Azienda Ospedaliero Universitaria Ospedali Riuniti)
The Lancet Oncology
July 19, 2012
10.1016/s1470-2045(12)70294-2
Cited by 145

Related Papers

Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer
|Journal of Clinical Oncology|2000|3.8k
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Isolation and <i>In vitro</i> Propagation of Tumorigenic Breast Cancer Cells with Stem/Progenitor Cell Properties
|Cancer Research|2005|1.7k